Xeris Biopharma Holdings, Inc.
XERS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $74,380 | $71,539 | $60,119 | $60,099 |
| % Growth | 4% | 19% | 0% | – |
| Cost of Goods Sold | $10,996 | $14,609 | $8,728 | $9,478 |
| Gross Profit | $63,384 | $56,930 | $51,391 | $50,621 |
| % Margin | 85.2% | 79.6% | 85.5% | 84.2% |
| R&D Expenses | $7,483 | $8,055 | $7,753 | $6,092 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $46,459 | $44,393 | $44,018 | $40,139 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2,711 | $0 | $2,710 | $2,711 |
| Operating Expenses | $56,653 | $52,448 | $54,481 | $48,942 |
| Operating Income | $6,731 | $4,482 | -$3,090 | $1,679 |
| % Margin | 9% | 6.3% | -5.1% | 2.8% |
| Other Income/Exp. Net | -$6,110 | -$6,410 | -$6,130 | -$6,792 |
| Pre-Tax Income | $621 | -$1,928 | -$9,220 | -$5,113 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $621 | -$1,928 | -$9,220 | -$5,113 |
| % Margin | 0.8% | -2.7% | -15.3% | -8.5% |
| EPS | 0 | -0.012 | -0.061 | -0.034 |
| % Growth | 100% | 80% | -76.4% | – |
| EPS Diluted | 0 | -0.012 | -0.061 | -0.034 |
| Weighted Avg Shares Out | 177,617 | 155,972 | 152,446 | 149,093 |
| Weighted Avg Shares Out Dil | 177,617 | 155,972 | 152,446 | 149,093 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,158 | $948 | $1,175 | $910 |
| Interest Expense | $7,268 | $7,358 | $7,305 | $7,703 |
| Depreciation & Amortization | $3,189 | $3,164 | $3,143 | $3,133 |
| EBITDA | $11,078 | $8,594 | $1,228 | $5,723 |
| % Margin | 14.9% | 12% | 2% | 9.5% |